Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for delirium

Journal of Palliative Medicine

Volumn 16, Issue 11, 2013, Pages 1335-1341

  Crawford, Gregory B ^a,b   Meera Agar, M ^c,d   Quinn, Stephen J ^e   Phillips, Jane ^f   Litster, Caroline ^c   Michael, Natasha ^g   Doogue, Matthew ^h   Rowett, Debra ^c   Currow, David C ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Central Adelaide Local Health Network   (Australia)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

^d Braeside Hospital   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f UNIVERSITY OF NOTRE DAME   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

ADULT; AGED; AKATHISIA; ARTICLE; COMORBIDITY; DAILY LIFE ACTIVITY; DELIRIUM; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GAIT; HEALTH CARE DELIVERY; HOSPICE CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; MYOCLONUS; ORTHOSTATIC HYPOTENSION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DELIRIUM; FEMALE; HALOPERIDOL; HOSPICES; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PHARMACOVIGILANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887915192     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2013.0230     Document Type: Article

References (20)

1. Leonard M, Agar M, Mason C, Lawlor P: Delirium issues in palliative care settings. J Psychosom Res 2008;65:289-298.
2. Breitbart W, Alici Y: Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 2012;30:1206-1214.
3. Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E, Jadad AR: Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: A systematic review. J Pain Symptom Manage 2001;22:631-634.
4. Fainsinger RL, Tapper M, Bruera E: A perspective on the management of delirium in terminally ill patients on a palliative care unit. J Palliat Care 1993;9:4-8.
5. Vella-Brincat J, Macleod AD Haloperidol in palliative care. Palliat Med 2004;18:195-201.
6. Hu H, Deng W, Yang H: A prospective random control study comparison of olanzapine and haloperidol in senile delirium. Chongging Med J 2004;8:1234-1237.
7. Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, Chapple S, Phillips B, et al: A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res 2010;69:485-490.
8. Devlin JW, Roberts RJ, Fong JJ, Skrobik Y, Riker RR, Hill NS, et al: Efficacy and safety of quetiapine in critically ill patients with delirium: A prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010;38:419-427.
9. National Institute for health and Clinical Excellence (NICE) Delirium: Diagnosis, prevention and management (Clinical guideline (CG)103:2010; http://guidance.nice.org.uk/CG103/Guidance/pdf/English) (Last accessed October 1, 2013).
10. Currow DC, Rowett D, Doogue M, To THM, Abernethy AP: An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. J Palliat Med 2012;15:282-286.
11. Currow DC, Shelby-James TM, Agar M, Plummer J, Rowett D, Glare P, Spruyt O, Hardy J: Planning phase III multi-site clinical trials in palliative care: The role of consecutive cohort audits to identify potential participant populations. Support Care Cancer 2010;18:1571-1578.
12. Currow DC, Vella-Brincat J, Clark K, Fazekas B, Doogue M, Rowett D: Pharmacovigilance in hospice/palliative care. Rapid report of net clinical effect of metoclopramide. J Palliat Med 2012;15:1071-1075.
13. Anon. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, V4.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocol Development/ electronic-applications/ctc.htm (Last accessed May 28, 2009).
14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt CJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therapeut 1981;30:239-245.
15. Abernethy AP, Shelby-James TM, Fazekas BS, Woods D, Currow DC: The Australian-modified Karnofsky Performance Status (AKPS) scale: A revised scale for contemporary palliative care clinical practice. BMC Palliat Care 2005;4:7.
16. Charlson ME, Pompei P, Ales KL, MacKenzie RC: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
17. Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M: Drug therapy for delirium in terminally ill adult patients. Cochrane Database Syst Rev 2012;11(Nov 14): CD004770.
18. Campbell N, Boustani MA, Ayub A, Fox GC, Munger SL, Ott C, Guzman O, Farber M, Ademuyiwa A, Singh R: Pharmacological management of delirium in hospitalized adults: A systematic evidence review. J Gen Intern Med 2009;24(7):848-853.
19. Seitz DP, Gill SS, Lvan Zyl LT: Antipsychotics in the treatment of delirium.Asystematic review JClin Psychiatry 2007;68:11-21.
20. Lacasse H, Guévin J-F, Perreault MM, Williamson DR: Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients Ann Pharmacother 2006;40):1966-1973.